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Chronic renal failure is a well-known long-term complication of methylmalonic aciduria (MMA-uria), occurring even under apparently 
optimal metabolic management. The onset of renal dysfunction seems to be dependent on  the type of defect and  vitamin B12-
responsiveness. We  report on  a patient with a vitamin B12-responsive cobalamin A type  (cblA) MMA-uria caused  by  a homozygous 
stop mutation (p.R145X) in  the cobalamin A gene (MMAA). She was  diagnosed with chronic kidney disease (CKD) stage III at the age of 
12 years. Following re-evaluation, the patient received vitamin B12 (hydroxocobalamin) treatment, resulting in a signiﬁcant decrease in the 
concentration of methylmalonic acid (MMA) in urine and  plasma. Until age 29 years glomerular ﬁltration rate remained stable probably 
due to hydroxocobalamin treatment slowing down progression to end-stage renal failure. Kidney biopsies showed non-speciﬁc  
manifestations  of chronic interstitial inﬂammation.  The  patient received a renal transplant at  age  35 years. Under continuous 
treatment with hydroxocobalamin there is no evidence of kidney damage due  to MMA-uria until the last follow-up 6 years after 
transplantation. 
This case report illustrates (i) a long-term follow-up of a patient with MMA-uria due  to cblA deﬁciency, (ii) the involvement of the kidney 
as a target organ and (iii) the importance of early and  adequate vitamin B12 substitution in responsive patients. Further investigation will be 
necessary to prove the protective effect of hydroxocobalamin in the kidney in vitamin B12-responsive patients. 
 
 
 
 
1. Introduction 
 
Methylmalonic aciduria (MMA-uria), ﬁrst described by the group 
of  Oberholzer et  al.  in  1967  [1],  belongs to the group of  organic 
acidurias.  It is biochemically characterized by the accumulation of 
speciﬁc organic acids  such  as methylmalonic acid  (MMA), propionate 
 
 
 
(PA),  3-OH-propionic acid  (3-OH-PA) and  2-methylcitric acid  (MC). 
The disease is caused either by mutations (mut0, mut−) in the enzyme 
methylmalonyl-CoA  mutase (MCM)  which is involved in  the break- 
down of branched chain  amino acids, odd-numbered chain  fatty acids, 
cholesterol side  chains and  other metabolites or by mutations in the 
genes MMAA (cblA),  MMAB (cblB)  and  MMADHC (cblD-variant2) 
encoding proteins important for the  synthesis of its cofactor 
adenosylcobalamin (AdoCbl) [2].  According to  the type of mutation 
and  resulting residual enzymatic activity, there is a wide  clinical  spec- 
trum of the disease. Typically, patients manifest with acute metabolic 
crisis during the  ﬁrst days of life or in catabolic states due  to infectious 
diseases or  prolonged fasting.  The metabolic crises  are  characterized 
by lactic acidosis, hyperketonaemia, hypo- or hyperglycaemia and 
hyperammonaemia and  may  result in metabolic encephalopathy and 
multi-organ failure.  Complications  include failure to  thrive,  develop- 
mental delay, mental retardation, muscular hypotonia, metabolic stroke 
like episodes with basal ganglia damage and  renal failure [3]. 
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The pathophysiology of chronic kidney disease (CKD) in MMA-uria 
is poorly understood. There  is evidence that the severity of the defect 
and  therefore the  concentration of MMA might play an important role 
[3]. The nature of the disease in the kidney is unclear for the lack  of 
speciﬁc biomarkers and  investigations of kidney biopsies at  an  early 
stage of the disease. Careful clinical descriptions combined with detailed 
studies of kidney biopsies are necessary to yield insights into the origin 
of kidney destruction. Here  we  present the 42-year history of renal 
involvement as well  as analysis of several kidney biopsies in a female 
patient with vitamin B12-responsive MMA-uria  due  to a homozygous 
stop  mutation in the  MMAA gene  (cblA). 
 
2. Case report 
 
The patient was  born  after uneventful pregnancy as the ﬁrst child 
to a non-consanguineous Caucasian couple. She presented at 3 days of 
life with icterus (bilirubin 340  μmol/l), muscular hypotonia, vomiting, 
weight loss and  lethargy. There  was no acidosis present (plasma bicar- 
bonate 25.4 mmol/l) and blood ammonia concentration was normal for 
a newborn (88  μmol/l). The ﬁrst proﬁle of amino acids  in plasma and 
urine revealed elevated concentrations of lysine  and  hyperlysinemia 
was  ruled out.  Under suspicion of a metabolic defect the  child  was 
put on a low  protein diet  (1.4  g protein/kg/d) and  improved remark- 
ably.  The  follow-up investigation of the amino acid  proﬁle showed 
hyperglycinemia  and   hyperglycinuria.  Accidental  protein  intake  of 
2 g/kg/d at 4 month of age led to a metabolic derailment which could 
be  easily   controlled  by  i.v.  glucose  application.  At  age   8 months 
the  urine was  screened for organic acids  and  high  concentrations  of 
MMA were detected in urine (4.3  mmol/d) and  plasma (255 μmol/l) 
establishing the diagnosis of MMA-uria.  Incorporation of label  from 
[14C]propionate into cell proteins in cultured ﬁbroblasts was  severely 
deﬁcient but showed a clear response to supplementation of the culture 
medium with high  concentrations of hydroxocobalamin. A cblA defect 
was  conﬁrmed by  somatic complementation and  later by  molecular 
genetic investigation which revealed a homozygous mutation in exon 
2  of  the MMAA  gene  (c.433C N T) predicting  an  amino acid  change 
from  arginine to a stop codon at position 145  (p.R145X). Vitamin B12 
concentration  was   low  (225 pmol/l) but within the normal range 
(220–730 pmol/l).  Intramuscular  injections of hydroxocobalamin for 
5 days did not change the concentration of excreted MMA. Accordingly, 
no treatment was started initially. The patient was kept on a low protein 
diet (1.4  g/kg/d) and  showed normal growth and  psychomotor devel- 
opment (IQ 98 at age 4 years  by J. Kramer's intelligence test) [Fig. 1]. 
At age 12 years, the patient showed impaired growth and CKD stage 
III  was   discovered (glomerular  ﬁltration  rate:  45 ml/min/1.73 m2, 
obtained by 24 h urine collection, [Fig. 2]). Until this  age, kidney func- 
tion had   not been documented so  that the onset of  CKD remains 
obscure. In addition, hyperuricemia (up  to 778  μmol/l) due  to reduced 
excretion of uric acid (19 μmol/kg/d, normal range 91 ± 50) was iden- 
tiﬁed and subsequently treated with a xanthine oxidase inhibitor (Allo- 
purinol®). Generalized signs  of proximal tubulopathy like that seen  in 
Fanconi  syndrome described by D'Angio et al. in a patient with MMA- 
uria  [4]  were not found.  Kidney  size  determined by  ultrasound was 
within the normal range. According to a previous publication [5] the 
responsiveness of this  patient to hydroxocobalamin was  re-evaluated 
and, this time, found to be positive. Treatment with hydroxocobalamin 
was  re-introduced using  a dosage of 2 × 10 mg/d p.o.  from  1983  to 
1995  and  1 × 10 mg/7d i.m. from  1995  to 2006.  Cofactor  responsive- 
ness  was  documented by impressive catch-up growth [Fig. 1] as well 
as  long-term decline in  urinary MMA excretion [Fig. 2], with mean 
MMA excretion decreasing from 3212  μmol/mmol creatinine before ad- 
ministration to 719  μmol/mmol creatinine (oral treatment) and further 
to 422  μmol/mmol creatinine (i.m. administration). Treatment included 
a low  protein diet as  well  as  carnitine (3 × 1 g/d) and  bicarbonate. 
Neurodevelopment remained normal (IQ 97 at age  22, by Hamburg- 
Wechsler-Intelligenztest für Erwachsene, (HAWIE-R)). 
Total kidney volume detected by ultrasound decreased during the 
following years  and  at 16 years  of age it was below two standard devi- 
ations compared to healthy peers. From 1988 she had arterial hyperten- 
sion   and   in  1989   (age 18),   at CKD stage  III (GFR  54 ml/min/m2, 
determined by inulin clearance), a renal biopsy  was  performed [Fig. 2, 
nr. 1, Fig. 3]. The main ﬁndings were areas with advanced tubular atro- 
phy and interstitial ﬁbrosis which were interspersed with mononuclear 
inﬁltrates. Immunohistochemistry and electron microscopy (EM) ruled 
out a glomerulonephritis or a hereditary glomerulopathy. Unfortunate- 
ly, the material was  not sufﬁcient to examine the tubulointerstitium 
by EM in respect to mitochondrial pathologies as seen  in the proximal 
tubules of a Mut knock-out mouse model [6]. 
From 1996 (age 25), renal function deteriorated. Another biopsy was 
performed in 1999  (age 28), [Fig. 2, nr. 2] showing a similar pattern as 
previously  reported.  However,  additionally  severe  arteriolosclerosis 
was  detected most probably due  to arterial hypertension.  One  year 
later renal replacement therapy had  to be started and  the patient was 
dependent on hemodialysis the following 6 years  [Fig. 2]. 
In 2006 (age 35) the patient underwent kidney transplantation from a 
deceased donor. After the transplantation she remained on a low protein 
diet as well as supplementation with hydroxocobalamin (1 × 4 mg/14d 
i.m.)  and  carnitine (3 × 1 g/d).  Immunosuppressive regimen consisted 
of tacrolimus (Prograf®, Astellas), mycophenolate-sodium  (Myfortic®, 
Novartis) and  prednisone. Prednisone was  tapered and  stopped three 
months after  transplantation.  The  estimated glomerular ﬁltration rate 
(eGFR)  according to  Cockroft   Gault  was   90 ml/min/1.73 m2.  Plasma 
MMA  concentration  decreased  from   304  μmol/l   to  a   baseline  of 
59 μmol/l  [Fig. 2]. Graft function remained stable and  surveillance biop- 
sies [Fig. 2, nr. 3, 4] were performed according to the  transplant protocol 
three and six months after transplantation revealing borderline and mod- 
erate tubulitis, respectively, both consistent with interstitial rejection. The 
latter was treated with steroid pulses. In the second year after transplan- 
tation (eGFR 68 ml/min/1.73 m2) a third renal biopsy [Fig. 2, nr. 5] was 
performed. Besides  minor arteriolosclerosis the morphology was  well 
preserved and  no further abnormalities were reported. Blood pressure 
was  well  controlled under antihypertensive treatment.  At  the last 
follow-up, six years  after transplantation, serum creatinine concen- 
tration was  95 μmol/l,  the eGFR was  70 ml/min/1.73 m2  and  there 
was neither glomerular nor tubular proteinuria detectable. 
 
3. Discussion 
 
We  present a  long-term follow-up of  a  patient with vitamin 
B12-responsive   cblA   type  MMA-uria    due   to  the   STOP  mutation 
p.R145X,  which is  the most common allele  found in  patients with 
CblA defects (representing 43% of pathogenic alleles) [7]. The case illus- 
trates progressive loss of kidney function ﬁnally leading to end  stage 
kidney failure  in  a patient with a rather mild  form  of MMA-uria,  in 
whom development and  growth are normal and  severe metabolic 
decompensations are  lacking.  It also  underscores the importance of 
standardized testing for cofactor responsiveness and  subsequent treat- 
ment with hydroxocobalamin in such patients. Our data clearly  suggest 
improved metabolic control on  i.m. application vs. oral  supplementa- 
tion. Given the risk of these patients for severe long-term complications 
(e.g. end stage  renal disease and optic  nerve atrophy) it is important to 
study the effects  of more aggressive management [8]. 
Patients with isolated MMA-uria, even mildly affected, are thought to 
be at risk of developing CKD [3]. High concentrations of MMA in urine are 
a known risk factor for the development of CKD in those patients [3]. The 
administration of vitamin B12  in our patient resulted in a signiﬁcant de- 
crease in urinary MMA excretion [Fig. 2]. Partial correction of the bio- 
chemical phenotype has  slowed the  progression from  CKD III to  end 
stage  renal disease. Only after  17 years  of vitamin B12  supplementation, 
the patient necessitated hemodialysis. Nevertheless, these results should 
be  interpreted with caution, since  the urinary excretion of MMA and 
other putatively toxic metabolites of alternative propionate oxidation 
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Fig. 1. Summary of physical growth. The percentiles show stature and weight-for-age. CKD was diagnosed because of a decline in growth at 12  years of age  as indicated by arrowhead. 
 
 
(e.g.  2-methylcitrate) diminishes with decreasing kidney function and 
thus accumulating toxic compounds could foster the naturally occurring 
disease progression despite hydroxocobalamin supplementation. Unfor- 
tunately, only very few plasma MMA levels are available during the peri- 
od before end  stage renal disease. The drop of mean plasma as well  as 
urinary MMA concentrations after  renal transplantation [Fig. 2] is most 
likely  due  to the transplant, as  the kidney is said  to  contribute to at 
least  18% of activity normally provided by the liver [9,10]. 
Several  mechanisms may  explain the pathophysiology of cellular 
damage in MMA. First, disturbances of the  tricarboxylic acid cycle and 
the  respiratory chain  as well  as disturbances in  the glutathione and 
dicarboxylate transport  are  thought to be  involved  in  the 
pathomechanism [11]. Secondary to mitochondrial dysfunction, oxida- 
tive  stress and  disturbances in mitochondrial DNA equilibrium might 
occur  [12–14]. Second,  accumulating dicarboxylic acids  may  be toxic, 
in particular in the  brain.  According to the “trapping  hypothesis”  im- 
paired transport of dicarboxylic acids  either at the blood-brain barrier 
or between astrocytes and  neurons as well as de novo  synthesis of di- 
carboxylic acids  in brain is causing brain damage [13,14].  Sauer  et al. 
[11,15]  suspect a similar pathomechanism of impaired function of di- 
carboxylic acid transporters and  accumulating mitochondrial toxins to 
be responsible for kidney damage in MMA-uria. 
The performed native kidney biopsies showed areas with remark- 
able tubular atrophy and interstitial ﬁbrosis interspersed with mononu- 
clear inﬁltrates without other abnormal ﬁndings which might reﬂect the 
inﬂuence of MMA-uria in the kidney [Fig. 3]. These observations ﬁt with 
the description of kidney biopsies taken from other patients with MMA- 
uria  due  to mut−  and  cblA deﬁciency [10,16].  Similarly,  the  graft biop- 
sies did  not  show any striking abnormalities which might be a hint at 
kidney damage caused by  MMA-uria.  This  ﬁnding matches with the 
group of Lubrano et al. [17] who  reported the case of a girl receiving a 
kidney transplant at the age of 17 years  because of MMA-uria  due  to a 
cblA defect.  In a 16.5 year follow-up study renal function remained sta- 
ble and re-biopsy did not show any striking abnormalities, even  during 
pregnancy [18]. In contrast to our  case,  this patient is on unrestricted 
diet  and has not been on hydroxocobalamin treatment [18, 19]. 
Because  of the small  number of organ transplantations in a pheno- 
typically highly  variable patients' population a clear  recommendation 
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Fig. 2. Course of glomerular ﬁltration rate (GFR) and concentration of MMA in an individual with cblA MMA-uria in dependence of hydroxocobalamin (OHCbl) treatment. Values for GFR 
indicated as triangles were obtained as mean, each single value obtained from a 24  h urine collection (n = 5 (1983), n = 6 (1984), n = 8 (1985), n = 5 (1986), n = 5 (1987), n = 8 
(1990), n = 7 (1991), n = 3 (1992), n = 4 (1994), n = 10 (1995), n = 5 (1996), n = 7 (1997), n = 4 (1998), n = 3 (1999)). GFR values indicated as squares were measured by inulin 
clearance, values indicated as circles were obtained by Cockroft Gault estimation. Urinary MMA concentrations [µmol/mmol creatinine] are depicted as a black line and plasma MMA con- 
centrations [µmol/l] as a dotted line. Error bars are represented by vertical lines. Kidney biopsies are indicated with arrowheads and numbered. Boxes show 4 periods of treatment with 
hydroxocobalamin (n = number of independently performed measurements): No hydroxocobalamin treatment (n = 47), 2 × 10  mg/d p.o. (n = 21), 1 × 10  mg/7d i.m. (urine: n = 42, 
plasma: n = 6), post transplantation 1 × 4 mg/14d i.m. (urine: n = 32, plasma: n = 28). The signiﬁcance has been determined by one-way ANOVA (*, **P b 0.05) for MMA concentration 
in urine and (***P b 0.05) for MMA concentration in plasma and is referring to the previous value. 
 
 
for organ transplantation in MMA-urias cannot be made. Thirty-one pa- 
tients with MMA-uria  with kidney (n  = 10),  liver  (n  = 15)  or com- 
bined liver/kidney transplantation (n  = 6) have  been reported so far 
[10,  16,  20–24] and  most of  them harbor a  mut0  (n  = 16)  defect. 
Some  patients underwent episodes of severe metabolic decompensa- 
tion, metabolic stroke or death [25] even  after  combined liver and  kid- 
ney  transplantation clearly  demonstrating that severe complications 
may  still  occur.  Nevertheless, the kidney seems to play  an  important 
role  for metabolic stability and  correction of MCM activity in the pa- 
tients as  kidney or  combined kidney/liver transplantation seems to 
lower MMA concentration more efﬁciently and provides more metabol- 
ic stability than single  liver  transplantation [10, 17, 24, 26]. This case 
report as well as the  ﬁndings of other groups [17, 24] in even  more se- 
vere  forms  of MMA-uria  suggest that elective kidney transplantation 
 
 
a) b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Native kidney biopsy (1989, age 18  years) showing dense inﬂammatory interstitial inﬁltrate (+), areas of tubular atrophy (*) and interstitial ﬁbrosis (#). Enrichment of protein casts 
close to the medulla–cortex region was reported as well as large areas with completely inconspicuously looking tubules (data not shown in the pictures). a) Periodic acid Schiff stain (PAS), 
LM, 200 ×; b) Masson's Trichrome Stain (TRI), LM, 200 ×. 
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may be a form of “cell-therapy” and regarded as an alternative and safer 
strategy than  liver  or  combined liver-kidney transplantation  for  it 
seems to restore sufﬁcient enzyme activity and  improves quality of 
life in patients. 
Several  cases  of hyperuricemia in  MMA-uria  have  been reported 
[10, 27] similar to the ﬁnding in our  patient. As suggested by the re- 
duced excretion of uric acid, one could  speculate that the  characteristi- 
cally accumulating organic acids – and MMA in particular – may induce 
tubular damage and inhibit the tubular secretion of uric acid. Uric acid is 
known to induce gout nephropathy via chronic interstitial inﬂammation 
[28] and might be an additional toxic factor in the development of CKD 
in MMA-uria. 
In conclusion this case report illustrates that CKD is a long term com- 
plication even  in patients with mild defects leading to almost no meta- 
bolic derailment. High concentrations of MMA are suspected to be 
nephrotoxic and  hydroxocobalamin can  lower MMA concentration in 
responsive patients.  Responsiveness  to hydroxocobalamin treatment 
should therefore be carefully evaluated and responsive patients should 
be adequately treated by parenteral administration since this may slow 
down the progress of CKD. Elective kidney transplantation seems to be a 
valid option in selected patients. To date, no evidence of recurrence of 
MMA-speciﬁc changes in the transplanted kidney has been evidenced; 
however, it has to be kept in mind that it is neither curative nor protec- 
tive against metabolic stroke. 
 
 
